表紙
市場調查報告書

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2) :開發中產品分析

Histone Deacetylase 2 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 363571
出版日期 內容資訊 英文 144 Pages
訂單完成後即時交付
價格
Back to Top
組蛋白去乙醯酵素2 (組蛋白去乙醯酶2) :開發中產品分析 Histone Deacetylase 2 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 144 Pages
簡介

本報告提供組蛋白去乙醯酵素2 (組蛋白去乙醯酶2)的開發情形相關的資訊,各開發階段、藥物標的、作用機制、給藥途徑及各分子類型的分析,,開發治療藥的企業概要,最新消息和新聞稿等資訊,為您概述為以下內容。

簡介

  • 調查範圍

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2)的概要

治療藥的開發

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):開發中的產品 - 各開發階段

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):開發中的產品 - 各治療範圍

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):開發中的產品 - 各適應症

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):企業開發中的產品

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):大學/機關開發中的產品

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):治療藥的評估

  • 各單劑療法/聯合治療產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2)的治療藥的開發企業

  • 4SC AG
  • Acetylon Pharmaceuticals, Inc.
  • Chipscreen Biosciences Ltd
  • Curis, Inc.
  • GlaxoSmithKline Plc
  • HitGen LTD
  • Italfarmaco S.p.A.
  • MEI Pharma, Inc.
  • Merck & Co., Inc.
  • Rodin Therapeutics
  • Sigma-Tau S.p.A.
  • TetraLogic Pharmaceuticals
  • Yungjin Pharm. Co., Ltd.

藥物簡介

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):暫停中的計劃

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):主要消息與新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2045TDB

Summary

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Histone deacetylase 2 is an enzyme encoded by the HDAC2 gene. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It forms transcriptional repressor complexes by associating with MAD, SIN3, YY1 and N-COR. It interacts in the late S-phase of DNA-replication with DNMT1 in the other transcriptional repressor complex composed of DNMT1, DMAP1, PCNA, and CAF1. It deacetylates TSHZ3 and regulates its transcriptional repressor activity.

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) pipeline Target constitutes close to 29 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 6, 1, 12 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Gastrointestinal, Immunology, Infectious Disease, Musculoskeletal Disorders and Respiratory which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Melanoma, Mycosis Fungoides, Alzheimer's Disease, B-Cell Non-Hodgkin Lymphoma, Breast Cancer, Burkitt Lymphoma, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Essential Thrombocythemia, Glioblastoma Multiforme (GBM), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Neuroblastoma, Non-Small Cell Lung Cancer, Parkinson's Disease, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Squamous Cell Carcinoma, Triple-Negative Breast Cancer (TNBC), Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Basal Cell Carcinoma (Basal Cell Epithelioma), Becker Muscular Dystrophy, Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Bone Disorders, Charcot-Marie-Tooth Disease Type II, Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), CNS Lymphoma, Cognitive Disorders, Colon Cancer, Depression, Duchenne Muscular Dystrophy, Epithelial Ovarian Cancer, Gallbladder Cancer, Gliosarcoma, Hemoglobinopathies, High-Grade Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Human Papillomavirus (HPV) Associated Cancer, Huntington Disease, Lewy Body Dementia, Liver Fibrosis, Lung Cancer, Merkel Cell Carcinoma, Metastatic Melanoma, Multiple Sclerosis, Myelofibrosis, Natural Killer Cell Lymphomas, Neurodegenerative Diseases, Non-Hodgkin Lymphoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral T-Cell Lymphomas (PTCL), Pick Disease, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Prostate Cancer, Recurrent Medulloblastoma, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Sezary Syndrome, Sickle Cell Disease, Solid Tumor, Systemic Lupus Erythematosus and Thalassemia.

The latest report Histone Deacetylase 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)
  • The report reviews Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Overview
  • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
  • 4D Pharma Plc
  • 4SC AG
  • Alkermes Plc
  • Bristol-Myers Squibb Co
  • Chipscreen Biosciences Ltd
  • Curis Inc
  • Italfarmaco SpA
  • Jubilant Biosys Ltd
  • Medivir AB
  • MEI Pharma Inc
  • Merck & Co Inc
  • Oceanyx Pharmaceuticals Inc
  • Regenacy Pharmaceuticals LLC
  • Shuttle Pharmaceuticals Inc
  • Yungjin Pharm Co Ltd
  • Zhejiang Hisun Pharmaceutical Co Ltd
  • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Drug Profiles
  • ACY-1035 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ACY-1071 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ACY-738 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ACY-957 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CS-3158 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..4), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by 4D Pharma Plc, H2 2019
  • Pipeline by 4SC AG, H2 2019
  • Pipeline by Alkermes Plc, H2 2019
  • Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Pipeline by Chipscreen Biosciences Ltd, H2 2019
  • Pipeline by Curis Inc, H2 2019
  • Pipeline by Italfarmaco SpA, H2 2019
  • Pipeline by Jubilant Biosys Ltd, H2 2019
  • Pipeline by Medivir AB, H2 2019
  • Pipeline by MEI Pharma Inc, H2 2019
  • Pipeline by Merck & Co Inc, H2 2019
  • Pipeline by Oceanyx Pharmaceuticals Inc, H2 2019
  • Pipeline by Regenacy Pharmaceuticals LLC, H2 2019
  • Pipeline by Shuttle Pharmaceuticals Inc, H2 2019
  • Pipeline by Yungjin Pharm Co Ltd, H2 2019
  • Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Dormant Products, H2 2019 (Contd..3), H2 2019
  • Dormant Products, H2 2019 (Contd..4), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top